Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population.
J Infect Chemother
; 28(9): 1273-1278, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1966847
ABSTRACT
INTRODUCTION:
The vaccine against SARS-CoV-2 provides humoral immunity to fight COVID-19; however, the acquired immunity gradually declines. Booster vaccination restores reduced humoral immunity; however, its effect on newly emerging variants, such as the Omicron variant, is a concern. As the waves of COVID-19 cases and vaccine programs differ between countries, it is necessary to know the domestic effect of the booster.METHODS:
Serum samples were obtained from healthcare workers (20-69 years old) in the Pfizer BNT162b2 vaccine program at the Toyama University Hospital 6 months after the second dose (6mA2D, n = 648) and 2 weeks after the third dose (2wA3D, n = 565). The anti-SARS-CoV-2 antibody level was measured, and neutralization against the wild-type and variants (Delta and Omicron) was evaluated using pseudotyped viruses. Data on booster-related events were collected using questionnaires.RESULTS:
The median anti-SARS-CoV-2 antibody was >30.9-fold elevated after the booster (6mA2D, 710.0 U/mL [interquartile range (IQR) 443.0-1068.0 U/mL]; 2wA3D, 21927 U/mL [IQR 15321.0->25000.0 U/mL]). Median neutralizing activity using 100-fold sera against wild-type-, Delta-, and Omicron-derived variants was elevated from 84.6%, 36.2%, and 31.2% at 6mA2D to >99.9%, 99.1%, and 94.6% at 2wA3D, respectively. The anti-SARS-CoV-2 antibody levels were significantly elevated in individuals with fever ≥37.5 °C, general fatigue, and myalgia, local swelling, and local hardness.CONCLUSION:
The booster effect, especially against the Omicron variant, was observed in the Japanese population. These findings contribute to the precise understanding of the efficacy and side effects of the booster and the promotion of vaccine campaigns.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Neutralizantes
/
COVID-19
/
Vacuna BNT162
/
Anticuerpos Antivirales
Tipo de estudio:
Estudio experimental
/
Estudio observacional
Tópicos:
Vacunas
/
Variantes
Límite:
Adulto
/
Anciano
/
Humanos
/
Middle aged
/
Young_adult
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
J Infect Chemother
Asunto de la revista:
Microbiologia
/
Terapia por drogas
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
J.jiac.2022.05.009
Similares
MEDLINE
...
LILACS
LIS